494 / 604
Author/year
# pts.
LNmet/
total
Primary
Fract x dose Local control
2-‐years
Survival
2-‐years
Severe morbidity
Kang 2010
26/59
CRC
3 x 12-‐17Gy
66%
66%
Grade 4 (n=2)
Bignardi 2011
19
Mixed
6 x 7.5Gy
78
NA
Grade 3 (n=1)
Petrongari 2011
12/12
Prostate
cancer
3 x 9-‐10Gy;
5 x 7Gy
3/12
NA
No
Bae 2012
18/41
CRC
3 x 15-‐17Gy
64%
(3-‐years)
60%
(3-‐years)
Grade>3 (n=3)
Jereczek-‐Fossa
2012
14/14
Prostate
cancer
3 x 10Gy
14/14
65%
No
Bercovic 2013
11/24
Prostate
cancer
10 x 5Gy
11/11
NA
No
De Vin 2014
88/309
Mixed
10 x 4-‐5Gy;
3 x 12Gy;
5 x 8.5Gy
33%
32%
(3-‐years)
NR
Fode 2015
6/201 Mixed (CRC)
3 x 15Gy
(isocenter)
6/6
58%*
No
Ost 2016
77/119 Prostate
Varying
93%
48%*
No
Retrospec+ve cohorts
Favorable local control, but lymph node metastasis
pa+ents not reported separately